Interestingly, one of the few FDA-approved applications of liquid biopsy is the Cobas EGFR Mutation Test v2 as a companion diagnostic test for EGFR TKI-eligible NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.